Recombinant
Recombinant Anti-Integrin beta 3 antibody [EPR2342] (ab119992)
- Datasheet
- References (12)
- Protocols
Overview
-
Product name
Anti-Integrin beta 3 antibody [EPR2342]
See all Integrin beta 3 primary antibodies -
Description
Rabbit monoclonal [EPR2342] to Integrin beta 3 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, Flow Cytmore details
Unsuitable for: ICC or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human Integrin beta 3 aa 750-850. The exact sequence is proprietary.
-
Positive control
- WB: THP-1 treated with TPA, HUVEC, Human spleen and Human plasma lysates. Flow Cyt: HUVEC cells.
-
General notes
A trial size is available to purchase for this antibody.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading... -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR2342 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab119992 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/1000. Detects a band of approximately 110 kDa (predicted molecular weight: 87 kDa). | |
| IP | 1/50. | |
| Flow Cyt | 1/20. |
Application notes
Is unsuitable for ICC or IHC-P.
Target
-
Function
Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Tissue specificity
Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis. -
Involvement in disease
Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors. -
Sequence similarities
Belongs to the integrin beta chain family.
Contains 1 VWFA domain. -
Post-translational
modificationsPhosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3690 Human
- Entrez Gene: 16416 Mouse
- Entrez Gene: 29302 Rat
- Omim: 173470 Human
- SwissProt: P05106 Human
- SwissProt: O54890 Mouse
- Unigene: 218040 Human
- Unigene: 87150 Mouse
see all -
Alternative names
- BDPLT16 antibody
- BDPLT2 antibody
- CD 61 antibody
see all
Images
-
![Western blot - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)](https://www.abcam.com/ps/products/119/ab119992/Images/ab119992-341252-ab119992.jpg)
Western blot - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)All lanes : Anti-Integrin beta 3 antibody [EPR2342] (ab119992) at 1/500 dilution
Lane 1 : U-87MG (Human glioblastoma-astrocytoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 2 : HEL (Human Erythroleukemia erythroblast) whole cell lysates with 5% NFDM/TBST
Lane 3 : LnCaP (Human prostate carcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 4 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 5 : HUVEC (Human umbilical vein endothelial cell) whole cell lysates with 5% NFDM/TBST
Lane 6 : PC-3 (Human prostate adenocarcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 7 : C2C12 (Mouse myoblasts myoblast) whole cell lysates with 5% NFDM/TBST
Lane 8 : Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysates with 5% NFDM/TBST
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 87 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?LnCaP, HeLa and PC-3 are low expression controls.
Exposure:
1,2 lane: 10 s;
3-8 lanes: 3 min
-
![Flow Cytometry - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)](https://www.abcam.com/ps/products/119/ab119992/Images/ab119992-311385-anti-integrin-beta-3-antibody-epr2342-flow-cytometry.jpg)
Flow Cytometry - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized HUVEC (Human umbilical vein endothelial cell) cell line labeling Integrin beta 3 with ab119992 at 1/20 (red) compared with a Rabbit monoclonal IgG (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077), at 1/2000 dilution was used as the secondary antibody.
-
![Western blot - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)](https://www.abcam.com/ps/products/119/ab119992/Images/ab119992-133591-anti-integrin-beta-3-antibody-epr2342-western-blot.jpg)
Western blot - Anti-Integrin beta 3 antibody [EPR2342] (ab119992)All lanes : Anti-Integrin beta 3 antibody [EPR2342] (ab119992) at 1/1000 dilution
Lane 1 : TPA treated THP1 cell lysate
Lane 2 : HUVEC cell lysate
Lane 3 : Human spleen lysate
Lane 4 : Human plasma lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 87 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?
Datasheets and documents
References
This product has been referenced in:
- He F et al. Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin avß3 inhibitors with nanoparticles in non-small cell lung cancer. Biosci Rep 39:N/A (2019). Read more (PubMed: 31316001) »
- Lomnytska M et al. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomark Res 6:2 (2018). Read more (PubMed: 29344361) »
